for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GlaxoSmithKline plc

GSK.L

Latest Trade

1,360.20GBp

Change

15.40(+1.15%)

Volume

3,883,976

Today's Range

1,335.00

 - 

1,361.60

52 Week Range

1,324.40

 - 

1,857.00

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
1,344.80
Open
1,339.60
Volume
3,883,976
3M AVG Volume
131.12
Today's High
1,361.60
Today's Low
1,335.00
52 Week High
1,857.00
52 Week Low
1,324.40
Shares Out (MIL)
5,017.38
Market Cap (MIL)
67,473.66
Forward P/E
--
Dividend (Yield %)
7.36

Next Event

Q3 2020 GlaxoSmithKline PLC Earnings Release

Latest Developments

More

AnaptysBio And GlaxoSmithKline Amend Strategic Immuno-Oncology Collaboration

GSK Says FDA Approves Nucala As Biologic Treatment For Hypereosinophilic Syndrome

BRIEF-Sanofi, GSK Sign Agreements With Canada For Up To 72 Million Doses Of Adjuvanted COVID-19 Vaccine

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About GlaxoSmithKline plc

GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.

Industry

Biotechnology & Drugs

Contact Info

G S K House, 980 Great West Road

TW8 9GS

United Kingdom

+44.20.80475000

https://www.gsk.com/

Executive Leadership

Jonathan Richard Symonds

Independent Non-Executive Chairman of the Board

Emma N. Walmsley

Chief Executive Officer, Executive Director

Iain James Mackay

Chief Financial Officer, Executive Director

Roger G. Connor

President - Vaccines

Brian McNamara

Chief Executive Officer - GSK Consumer Healthcare

Key Stats

2.48 mean rating - 27 analysts
Sell
Hold
Buy
Revenue (MM, GBP)

2017

30.2K

2018

30.8K

2019

33.8K

2020(E)

34.7K
EPS (GBp)

2017

111.800

2018

119.400

2019

123.900

2020(E)

115.951
Price To Earnings (TTM)
10.11
Price To Sales (TTM)
1.93
Price To Book (MRQ)
4.90
Price To Cash Flow (TTM)
8.50
Total Debt To Equity (MRQ)
233.13
LT Debt To Equity (MRQ)
189.26
Return on Investment (TTM)
15.87
Return on Equity (TTM)
9.92

Latest News

Latest News

GSK-J&J's long-acting HIV injection gets EU panel endorsement

GlaxoSmithKline Plc said an injection of its cabotegravir drug given every two months, in combination with Johnson & Johnson's rilpivirine, was recommended for approval to treat HIV infections by a panel of the European health regulator.

GSK's long-acting HIV injection endorsed by EU panel

GlaxoSmithKline Plc said on Friday an injection of its cabotegravir drug given every two months along with Johnson & Johnson's rilpivirine was recommended for approval to treat HIV infections by a panel of the European health regulator.

GSK to widen COVID-19 antibody treatment trial after safety clearance

GlaxoSmithKline and partner Vir Biotechnology will expand their trial of an experimental antibody to treat COVID-19 after initial use by a group of volunteers did not raise any safety concerns.

U.S. appeals court revives Glaxo $235.5 million verdict against Teva

A federal appeals court on Friday reinstated a 2017 jury verdict ordering Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc $235.5 million for selling a generic version of Glaxo's heart drug Coreg.

U.S. appeals court revives GlaxoSmithKline verdict against Teva

A federal appeals court on Friday reinstated a 2017 jury verdict that required Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent for its blood pressure drug Coreg.

GSK executive wary of human challenge trials for COVID-19 vaccine

GlaxoSmithKline Plc executive Thomas Breuer said on Tuesday he has "reservations" against human challenge trials as a tool for determining the effectiveness of COVID-19 vaccine candidates without a therapy for the infection.

China's Clover says its coronavirus vaccine candidate showed promise in animal test

An experimental coronavirus vaccine developed by China's Clover Biopharmaceuticals appeared to be safe and able to trigger immune responses in animal tests, researchers have said.

EU pays $384 million for Sanofi-GSK COVID vaccine as WHO scheme deadline looms

The European Union has agreed to buy a potential COVID-19 vaccine from Sanofi and GSK in its second such deal to secure supplies, as a deadline for joining the World Health Organization's (WHO) vaccine purchase programme looms.

GSK wins injunction against Boehringer inhaler marketing claims

Drugmaker GlaxoSmithKline has won a preliminary injunction barring rival Boehringer Ingelheim from making statements GSK claims are misleading in order to promote its inhalers as superior.

GSK loses bid to keep Avandia documents secret

Expert reports filed in a sprawling multidistrict litigation over GlaxoSmithKline's marketing of its diabetes drug Avandia must be unsealed, a federal judge in Philadelphia has ruled, rejecting the company's argument that the reports should stay secret to avoid eroding Avandia...

Sanofi, GSK launch trial for COVID-19 protein-based vaccine

French drugmaker Sanofi and Britain's GlaxoSmithKline said they had started a clinical trial of their protein-based COVID-19 vaccine candidate, and aimed to reach the final testing stage by December.

GSK, partner Vir join race to find COVID-19 antibody treatment

GlaxoSmithKline and partner Vir Biotechnology have started testing their experimental antibody on early-stage COVID-19 patients, entering the race to find a winner in a promising class of antiviral drugs to combat the pandemic.

U.S. FDA approves GlaxoSmithKline's blood cancer drug

The U.S. Food and Drug Administration on Wednesday approved GlaxoSmithKline's experimental treatment for a common form of blood cancer.

U.S. to pay $2.1 billion to Sanofi, GSK, in COVID-19 vaccine deal

The U.S. government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc for COVID-19 vaccines to cover 50 million people and to underwrite the drug makers' testing and manufacturing, the companies said on Friday.

UPDATE 1-U.S. to pay $2.1 bln to Sanofi, GSK, in COVID-19 vaccine deal

The U.S. government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc for COVID-19 vaccines to cover 50 million people and to underwrite the drugmakers' testing and manufacturing, the companies said on Friday.

Sanofi, Glaxo advance talks to supply up to 300 million COVID-19 vaccine doses to Europe: companies

Sanofi SA <SASY.PA> and GlaxoSmithKline Plc <GSK.L> on Friday said they are in advanced discussions with the European Commission to supply up to 300 million doses of the drugmakers's experimental COVID-19 vaccine.

FACTBOX-U.S. pours billions into securing access to coronavirus vaccine candidates

As drugmakers race to develop vaccines and therapies for the novel coronavirus, the United States is rushing to secure access to them. The U.S. government has agreed to invest more than $7 billion in vaccines and has funded more than 30 projects, including for diagnostics...

U.S. to pay $2.1 bln to Sanofi, GSK, in COVID-19 vaccine deal

The U.S. government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc for COVID-19 vaccines to cover 50 million people and to underwrite the drug makers' testing and manufacturing, the companies said on Friday.

Britain secures 60 million doses of Sanofi/GSK coronavirus vaccine

Britain has signed a deal for up to 60 million doses of a potential coronavirus vaccine being developed by Sanofi and GlaxoSmithKline (GSK), it said on Wednesday, its latest such arrangement as the race to tame the pandemic heats up.

BRIEF-GSK Q2 Adjusted EPS 19.2 Pence

* GSK - CONTINUE TO BELIEVE THAT MULTIPLE OPTIONS WILL BE NEEDED TO PREVENT AND TREAT COVID-19

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up